Increased expression of fatty acid synthase (FAS) is observed in a clinically aggressive subset of various common cancers and interference with FAS oers promising opportunities for selective chemotherapeutic intervention. The mechanisms by which FAS expression is (up)-regulated in these tumors remain, however, largely unknown. Recently we demonstrated that in LNCaP prostate cancer cells FAS expression is markedly elevated by androgens via an indirect pathway involving sterol regulatory element-binding proteins (SREBPs). Here, we also show that growth factors such as EGF are able to stimulate FAS mRNA, protein and activity. Several observations also indicate that the eects of EGF on FAS expression are ultimately mediated by SREBPs. EGF stimulates SREBP-1c mRNA expression and induces an increase in mature nuclear SREBP-1. Moreover, in transient transfection studies EGF stimulates the transcriptional activity of a 178 bp FAS promoter fragment harboring a complex SREBP-binding site. Deletion or mutation of this binding site abolishes these eects and ectopic expression of dominant negative SREBP-1 inhibits FAS expression and induction in intact LNCaP cells. Given the frequent dysregulation of growth factor signaling in cancer and the key role of SREBP-1 in lipid homeostasis, growth factor-induced activation of the SREBP pathway is proposed as one of the mechanisms responsible for upregulation of lipogenic gene expression in a subset of cancer cells. Oncogene (2000) 19, 5173 ± 5181.
Introduction
A substantial subset of common human cancers including cancers of the prostate, breast, ovary, colon, oral tongue, thyroid and endometrium, expresses elevated levels of fatty acid synthase (FAS), a key anabolic enzyme that catalyses the terminal steps in the de novo biosynthesis of fatty acids (Shurbaji et al., 1992; Hardman et al., 1995; Jensen et al., 1995; Epstein et al., 1995; Alo' et al., 1996 Alo' et al., , 1999 Rashid et al., 1997; Gansler et al., 1997; Milgraum et al., 1997; Krontiras et al., 1999; Pizer et al., 1998a; Vlad et al., 1999; Visca et al., 1999; Swinnen et al., 2000; Chambon et al., 1989) . In several of these cancers, elevated FAS expression is associated with more advanced disease and portends a poor prognosis. This dierence in expression between normal tissues and cancer has led to the development of a novel strategy for antineoplastic intervention. In fact, recent studies show that pharmacological inhibition of FAS leads to selective cytotoxicity in FAS-(over)expressing cancer cell lines and delays disease progression in xenograft models (Kuhajda et al., 1994; Furuya et al., 1997; Pizer et al., 1996a Pizer et al., ,b,c 1998b Pizer et al., , 2000 .
Although the molecular mechanisms that underly the regulation of FAS in typical lipogenic tissues have been the subject of numerous investigations, little is known about the regulation of FAS (over)expression in cancer cells. One important clue, however, is the recent ®nding that in prostate cancer, FAS is overexpressed at the mRNA level together with other enzymes of the same metabolic pathway (Swinnen et al., 2000) . This ®nding suggests that overexpression of FAS may be related to conditions promoting changes in the expression and/or activity of transcription factors involved in the coordination of lipogenic gene expression.
In the human prostate cancer cell line LNCaP, we have recently demonstrated that FAS expression is markedly elevated by androgens and that this stimulation involves the action of sterol-regulatory elementbinding proteins (SREBPs) (Swinnen et al., 1997a,b; Swinnen and Verhoeven, 1998) . These are a family of three basic helix ± loop ± helix transaction factors (SREBP-1a, -1c, and -2) that play a key role in the co-ordination of lipogenic gene expression and in cellular lipid homeostasis . Essential for their role as regulators of cellular lipid homeostasis is the feature that SREBPs are synthesized as inactive membrane-bound precursors that are activated by the newly discovered mechanism of regulated intramembrane proteolysis (Rip) (Brown et al., 2000) . Upon proteolytical cleavage (triggered by for instance cholesterol depletion) the amino-terminal part of the SREBP protein is released. It translocates to the nucleus and binds to so-called sterol regulatory elements (SREs) and certain E-boxes to co-ordinately regulate the expression of multiple lipogenic genes, including FAS (MaganÄ a and Osborne, 1996) .
Recent reports indicate that signal transduction by androgens in prostate cancer cells can also be turned on or can be enhanced by cytokines and growth factors (Culig et al., 1995a (Culig et al., ,b, 1996 Hobisch et al., 1998; Yeh et al., 1999; Craft et al., 1999) . As the expression and/ or signaling of these factors are frequently dysregulated in cancer cells (see Djakiew, 2000 , for review), we examined whether growth factors may contribute to the up-regulation of FAS expression in prostate cancer cells. Here, we demonstrate that epidermal growth factor (EGF) is indeed able to stimulate FAS expression in LNCaP cells. We provide evidence that also this eect involves activation of the SREBP pathway. In view of recent reports that signaling by the EGF receptor family is frequently activated as cancer progresses towards a more advanced disease (Djakiew, 2000) , these ®ndings suggest that growth factor activation of the SREBP pathway may be one of the mechanisms responsible for the up-regulation of FAS expression in a subset of cancer cells.
Results

Treatment with EGF stimulates FAS expression in LNCaP cells
To examine whether aberrant expression and/or signaling of growth factors such as EGF may contribute to the up-regulation of FAS expression in prostate cancer cells, we treated LNCaP prostate cancer cells with EGF. One day later, total RNA was prepared and analysed for FAS mRNA expression by Northern blot analysis. As demonstrated in Figure 1a , treatment with EGF (10 ng/ml) led to a threefold increase in a single 9 kb FAS mRNA species. This increase in FAS mRNA expression was accompanied by a 3 ± 4-fold stimulation of the expression of the 260 kDa FAS monomer (Figure 1b) . Similar changes were observed at the level of FAS activity, as revealed by incorporation studies of [C 14 ] from C 14 -labeled malonyl-CoA (Figure 1c ). Analogous to our earlier observation that stimulation of FAS expression in LNCaP cells (in that case by androgens) is accompanied by a marked accumulation of neutral lipids (Swinnen et al., 1996) , LNCaP cells cultured for 4 days in the presence of EGF displayed a marked increase in neutral lipid accumulation (Figure 2 ), con®rming that EGF has major eects on lipid metabolism in LNCaP cells. Interestingly, also related growth factors such as heregulin-b, have similar eects on lipid accumulation in LNCaP cells (data not shown).
Effects of EGF on FAS promoter-reporter activity
Analogous to our studies on the regulation of FAS expression by androgens, we examined whether EGF treatment aects the activity of a well-characterized 178 bp FAS promoter-reporter construct (Swinnen et al., 1997b) (Figure 3a) . The FAS promoter fragment present in this construct harbors a complex region of multiple SREBP binding sites, which mediate the eects of androgens and sterols on FAS promoter Figure 1 Impact of EGF on FAS mRNA, protein and activity in LNCaP cells. LNCaP cells were incubated in serum-free medium in the absence (7) or presence (+) of 10 ng/ml EGF. After 24 h, cells were harvested and examined for FAS mRNA expression by Northern blot analysis using a radiolabeled FAS cDNA probe (a). Hybridization signals were quantitated and corrected for dierences in RNA loading as revealed by hybridization with an 18S rRNA probe. Forty hours after EGF addition total cellular extracts were made. Equal amounts of protein were subjected to Western blot analysis using an anti-FAS antiserum (b). FAS activity (c) was determined on cell extracts by measuring the incorporation of [ formaldehyde in PBS, cultures were stained with Oil red O and counterstained with methylgreen as described before (Swinnen et al., 1996) activity (Swinnen et al., 1997b; MaganÄ a and Osborne, 1996) . LNCaP cells were transiently transfected with this promoter-reporter construct and then incubated in the presence or absence of EGF. Figure 3 shows that EGF treatment resulted in a more than threefold increase in reporter activity. Taken together, these ®ndings indicate that stimulation of FAS expression takes place at least in part at the transcriptional level and is mediated by cis-acting elements present in the proximal FAS promoter.
Involvement of SREBP-binding sites in the regulation of lipogenic gene expression by EGF
To examine whether the eects of EGF on FAS promoter activation are mediated by the SREBPbinding sites present in the proximal FAS promoter, LNCaP cells were transiently transfected with the wild type FAS promoter-reporter construct as above, or with a truncated construct in which the region responsible for SREBP binding is deleted ( Figure  4a ). As con®rmed by sterol depletion, this latter construct does not respond to activation of the SREBP pathway, whereas the wild type construct does (Figure 4b) . Similarly, the eects of EGF on FAS promoter activity were severely diminished when the SREBP-binding site was deleted (Figure 4b ). However, as this binding site is composed of two sterol-responsive elements (SREs) which overlap with an E-box (MaganÄ a and Osborne, 1996) , the possibility that factors other than SREBPs (e.g. USF, which is able to bind to the E-box) are involved in this response cannot be excluded. We therefore complemented these experiments with transient transfections with promoter-reporter constructs based on the proximal promoter region of the HMG-CoA synthase gene. As shown before (Inoue et al., 1998) and as con®rmed in Figure 5 , this gene responds to the activation of the SREBP pathway via two well-de®ned SREs (SRE1 and SRE2), the ®rst of which is the most important one. Similar to the eects of sterol depletion (Figure 5b ), EGF treatment resulted in transcriptional activation of the wild type promoter. Mutation of SRE1 abolished the eects of EGF, and mutation of SRE2 resulted only in a partial decrease in activation. Figure 3 , or with a similar construct in which the SRE site was deleted (FASdelSRE) (a). To examine the eects of EGF (b), transfected cells were incubated in serum-free medium in the presence or in the absence of 10 ng/ml EGF. After 16 ± 24 h of incubation, cells were lysed. Luciferase activity was measured and was expressed as per cent increase after treatment with EGF. As a control for the functionality of the constructs, similar experiments were carried out, but instead of the EGF treatment, sterol levels were modulated by incubating the cultures in lipoprotein-de®cient medium supplemented either with mevastatin or with 25-hydroxycholesterol). Luciferase activity was expressed as per cent increase after cholesterol depletion. Data shown are representative for three independent experiments. Columns, mean of incubations performed in triplicate; Bars, s.e.m.
EGF treatment results in a rapid increase in nuclear accumulation of mature SREBP-1
Activation by the SREBP pathway by typical inducers such as cholesterol depletion, involves proteolytic cleavage of SREBP precursors, ultimately resulting in an increase in mature nuclear SREBP. To examine whether also EGF treatment leads to changes in nuclear SREBP content, LNCaP cells were treated with EGF for dierent periods of time and nuclear extracts were prepared. These extracts were subjected to Western blot analysis with an antiserum against the aminoterminal part of SREBP-1. As demonstrated in Figure 6 , the nuclear content of mature SREBP-1, apparent as a 66 kDa protein, was increased as early as 30 min after EGF treatment and remained elevated for at least 24 h.
EGF treatment stimulates SREBP-1c mRNA expression in LNCaP cells
The SREBP-1 gene encodes two transcripts, originating from two dierent promoters. The SREBP-1a transcript encodes an SREBP that functions as a powerful transcriptional activator of a wide variety of lipogenic genes, including most genes involved in fatty acid and cholesterol synthesis (Pai et al., 1998; Shimano et al., 1996) . SREBP-1c, on the other hand, is less active but displays a higher degree of speci®city for genes involved in fatty acid synthesis (Pai et al., 1998; Shimano et al., 1997) . In view of recent reports that hormones such as insulin aect the SREBP pathway at multiple levels and speci®cally modulate the expression of one of these forms (in casu SREBP-1c) (Foretz et al., 1999b) , we examined whether also EGF (dierentially) aects the expression of SREBP-1 transcripts. LNCaP cells were cultured in the absence or presence of EGF for 24 h and total RNA was prepared and analysed for SREBP-1a and SREBP-1c expression by Northern blot analysis. As shown in Figure 7 , EGF did not aect SREBP-1a mRNA levels. In contrast, a twofold increase in the steady state mRNA levels for SREBP-1c was observed after EGF treatment.
Effect of dominant-negative SREBP expression on EGF induction of FAS gene expression
To further substantiate the role of SREBPs in the activation of FAS promoter activity by EGF, a dominant-negative form of SREBP-1c was introduced in LNCaP cells. This dominant-negative form was generated by introduction of a point mutation in the LNCaP cells were transiently transfected with a plasmid containing a luciferase reporter gene driven by a HMG-CoA synthase promoter fragment, harboring two well-de®ned SREs (SRE-1 and SRE-2)¯anked by auxiliary binding sites for NF-Y and Sp1 (SYNwt), or with a similar construct in which either SRE-1 or SRE-2 was mutated (SYN mutSRE-1) and SYN mutSRE-2) (a). To examine the eects of EGF (b), transfected cellls were incubated in serum-free medium in the presence or in the absence of 10 ng/ml EGF. After 16 ± 24 h of incubation, cells were lysed. Luciferase activity was measured and was expressed as per cent increase after treatment with EGF. As a control for the functionality of the constructs, similar experiments were carried out, but instead of EGF treatment, sterol levels were modulated. Data shown are representative for three independent experiments. Columns, mean of incubations performed in triplicate; Bars, s.e.m. Figure 6 Eects of EGF on the nuclear content of mature SREBP-1. At the indicated times after addition of EGF (10 ng/ ml), LNCaP cells were harvested and a crude nuclear fraction was prepared. Equal amounts of proteins were subjected to SDS ± PAGE and Western blot analysis with mAb IgG-2A4, directed against the amino-terminal part of SREBP-1. Immunoreactive bands were visualized using a peroxidase-coupled goat anti-mouse secondary antibody and a chemiluminescent Western blot analysis system. The data shown are representative of two independent experiments Figure 7 Regulation of SREBP-1a and SREBP-1c mRNAs by EGF. The same blot as shown in Figure 1a was hybridized with probes for SREBP-1a and SREBP-1c amino-terminal fragment of SREBP-1c (amino acids 1 ± 403), which is readily directed to the nucleus, replacing tyrosine at amino acid 320 by alanine. This mutation abolishes the binding of SREBP-1c to both sterol-regulatory elements and E-boxes, but still allows dimerization leading to a decreased availability of endogenous SREBP-1. In order to study the impact of dominant-negative SREBP-1c directly on the expression of the endogenous FAS gene, rather than on promoter-reporter constructs, we used an adenoviral system to deliver eciently the transgene into LNCaP cells. As determined in separate experiments with a green¯uorescent protein (GFP) the transgene could be transferred to approximately 80% of the cells at a multiplicity of infection of 30 pfu/cell (data not shown). When this adenoviral system was used to introduce the dominant-negative form of SREBP-1 (Ad-DN) into LNCaP cells, a decrease in basal FAS mRNA expression was noticed (Figure 8 ). Eects of EGF were completely abolished. To ascertain that this reduction of FAS expression was due to dominantnegative SREBP-1 expression and not to nonspeci®c adverse eects related to the viral infection, similar experiments were carried out with an adenovirus lacking the dominant-negative SREBP-1 insert. As shown in Figure 8 , infection with this virus had little or no in¯uence on the eects of EGF, nor on basal FAS expression levels. Moreover, endogenous SREBP-1 expression remained unaected by DN-SREBP-1 expression, indicating that the observed eects on FAS expression are speci®c and are not related to squelching or some other genera eect on gene transcription (Figure 8 ).
Mechanism of EGF activation of the SREBP-1 pathway
To explore the mechanism by which EGF activates the SREBP-1 pathway we pretreated LNCaP cells with inhibitors of dierent signal transduction pathways known to be activated by EGF. Of all components used (U0126, PD98059, Wortmannin, and LY-294002), only U0126, a potent inhibitor of the ERK/MAP kinase pathway (Favata et al., 1998) , nearly completely abolished the eects of EGF on FAS expression both at the mRNA level (Figure 9a ), and in transient transfection studies (Figure 9b ). PD98059 (another selective ERK/MAP kinase inhibitor) partially inhibited EGF action (Figure 9a ). Also Wortmannin (an inhibitor of the PI3 kinase pathway) exerted some inhibitory eect (Figure 9a ). LY-294002 (another inhibitor of the PI3 kinase pathway) decreased basal FAS expression, but only marginally aected the induction by EGF. These ®ndings, together with a recent report that U0126 may not be entirely selective but aects multiple signal transduction pathways Figure 8 The eect of a dominant-negative SREBP form on basal and EGF induced FAS mRNA expression. LNCaP cells were cultured either without adenovirus (no virus), with adenovirus expressing a dominant-negative form of SREBP-1 (Ad-DN, 30 pfu/cell), or with adenoviruses without insert (AdNull). The next day EGF (10 ng/ml) was added as indicated. One day later, cells were harvested and examined for the expression of FAS, endogenous SREBP-1 and dominant-negative SREBP-1 Figure 9 Impact of signal transduction inhibitors and dominant negative MEK on EGF induction of FAS expression. (a) LNCaP cells, pretreated with various inhibitors of dierent signal transduction pathways or with DMSO vehicle, were incubated in the absence (7) or presence (+) of EGF (10 ng/ml) for 24 h. Total RNA was prepared and analysed for FAS mRNA expression. U0126, 10 mM; PD98059, 40 mM, Wortmannin, 100 nM; LY-294002, 50 mM. (b) LNCaP cells were transiently transfected with a plasmid containing the wild type FAS promoter-reporter construct as in Figure 3 . Cells were pretreated with U0126 (10 mM) or with DMSO vehicle and further incubated in the presence or in the absence of 10 ng/ml EGF. After 16 ± 24 h of incubation, cells were lysed. Luciferase activity was measured and was expressed in relative luciferase units (RLU). (c) LNCaP cells were transiently transfected with a plasmid containing the wild type FAS promoter-reporter construct in the presence of an expression construct encoding dominant-negative MEK or a matching empty vector (Control). Luciferase activity was measured and was expressed in relative luciferase units (RLU) (Fukazawa and Uehara, 2000) , suggest that the eects of EGF on lipogenic gene expression are complex and involve activation of and/or cross-talk between multiple signal transduction pathways. Consistent with this view is our ®nding that cotransfection with a construct expressing dominant-negative MEK only partially prevents EGF activation of FAS gene transcription (Figure 9c) .
In view of previous reports that growth factors, including EGF, can activate the androgen receptor and enhance androgen receptor-mediated reporter gene transcription in transient transfection studies (Culig et al., 1995a (Culig et al., ,b, 1996 , experiments were designed to test to which extent the androgen receptor is involved in the eects of EGF. In a ®rst series of experiments, LNCaP cells were transiently transfected with a FAS promoterreporter construct and before addition of EGF were pretreated with Casodex (bicalutamide), a selective androgen receptor antagonist. Figure 10 shows that Casodex decreased basal FAS promoter activity but did not in¯uence the activation by EGF. Similarly, when EGF was administered together with low, suboptimal concentrations of androgens (in this case the synthetic androgen R1881), no synergistic or potentiating eects were seen ( Figure 10 . In a separate line of experiments to explore the involvement of the androgen receptor, EGF eects on FAS promoter activity were assessed in two prostate cell lines that do not express the androgen receptor (PC-3 and DU-145). In these cell lines, no eects of EGF were observed. Reintroduction of the androgen receptor by transient transfection with an androgen receptor expression construct did not restore the responsiveness to EGF (data not shown). These ®ndings indicate that the presence of the androgen receptor per se is not sucient for EGF to activate FAS gene expression.
Discussion
An ever-growing body of evidence indicates that FAS expression is elevated in a substantial subset of various human cancers. In prostate cancer, we have recently demonstrated that FAS expression is up-regulated at the mRNA level together with other enzymes of the same metabolic pathway (Swinnen et al., 2000) , suggesting that upregulation of FAS expression in prostate cancer (and probably also in other cancers ) is related to conditions leading to changes in the expression and/or activity of lipogenic transcription factors. Consistent with this hypothesis, FAS expression was found to be markedly stimulated by androgens in the human prostate cancer cell line LNCaP through activation of the SREBP pathway (Swinnen et al., 1997b) . Given the ability of growth factors and cytokines to activate or enhance the androgen signaling pathway in prostate cancer cells, we initiated a study to examine whether the previously observed dysregulation of the expression and/or signaling of these factors may contribute to the upregulation of FAS expression in prostate cancer cells.
In the present paper we show that growth factors such as EGF are indeed able to stimulate FAS mRNA, protein and activity in LNCaP cells. Compared to the 3 ± 5-fold increase in FAS expression elicited by synthetic androgens (Swinnen et al., 1997a) , the eects of EGF (2 ± 3-fold increase) are substantial and are only slightly less pronounced. Several lines of evidence indicate that, similar to the earlier reported eects of androgens, EGF-induced FAS expression involves activation of the SREBP pathway. The use of various inhibitors of dierent downstream signal transduction pathways together with expression constructs encoding dominant-negative eectors, suggests that the eects of EGF on lipogenic gene expression are complex and involve activation of and/ or cross-talk between multiple signal transduction pathways. In keeping with this ®nding are recent reports that in other experimental settings, the SREBP pathway is aected both by the ERK/MAP kinase pathway and by the PI3 kinase pathway (Kotzka et al., 1998 (Kotzka et al., , 2000 Fleischmann and Iynedjian, 2000) . Consistent with this complexity is the observation that EGF acts at multiple sites of the SREBP pathway: EGF induces a rapid increase in mature nuclear SREBP-1 and enhances the expression of SREBP-1c transcripts. To which extent also the androgen receptor is involved in the activation of the SREBP pathway by EGF remains, despite intense investigation, unclear. (i) The eects of EGF are not inhibited by the antiandrogen Casodex, suggesting that the androgen receptor is not involved, or that the actions of EGF are independent of the ligand-binding domain. (ii) EGF was not able to Figure 10 Eects of antiandrogens or low concentration of androgens on EGF induction of FAS promoter activity. LNCaP cells were transiently transfected with a plasmid containing the wild type FAS promoter-reporter construct as in Figure 3 . Cells were pretreated for 2 h with the androgen receptor antagonist Casodex (10 75 M), with suboptimal concentrations of the synthetic androgen R1881, or with ethanol vehicle, and were further incubated in the presence or in the absence of 10 ng/ml EGF. After 16 ± 24 h of incubation, cells were lysed. Luciferase activity was measured and was expressed in relative luciferase units (RLU) enhance or potentiate the eects of low suboptimal concentrations of androgen. (iii) Reintroduction of the androgen receptor in androgen-receptor negative cell lines does not restore the response to EGF. (iv) The time courses of EGF and androgen-induced activation of the SREBP pathway are dierent. Eects of EGF are faster than those of androgens (Swinnen et al., 1997b and unpublished observations) . Nonetheless, the androgen receptor has been shown to be aected by growth factors and has been proposed as a direct target for ERK/MAP kinases (Yeh et al., 1999) . Hence, the picture that emerges is one of a complex interplay of pathways that activate the SREBP pathway at dierent levels, ultimately resulting in increased lipogenesis. Our ®nding that SREBP-1 functions as a mediator of the lipogenic eects of growth factors is in agreement with the observation that in addition to FAS also other lipogenic genes of the same metabolic pathway (e.g. acetyl-CoA carboxylase, data not shown) are regulated by EGF. In view of the co-ordinated regulation of lipogenic genes in cancers in vivo and the reported dysregulation of growth factor expression and signaling in these cancers, our ®ndings suggest that activation of the SREBP pathway by growth factors may contribute to the up-regulation of lipogenic gene expression in a substantial subset of cancers. The question then arises whether overexpression of FAS plays an active role in cancer evolution, or whether this increase is merely the consequence of aberrant activation of regulatory pathways.
Materials and methods
Cell culture
The human prostate carcinoma cell lines LNCaP, PC-3 and DU-145 were obtained from the American Type Culture Collection (Manassas, VA, USA) and were maintained as described before (Swinnen et al., 1997a) . Human recombinant epidermal growth factor (EGF) was purchased from Sigma (St Louis, MO, USA). Where indicated, EGF was added to a ®nal concentration of 10 ng/ml, the optimal cencentration for growth stimulation in serum-free conditions (Schuurmans et al., 1988) . U0126 was obtained from Promega (Madison, WI, USA). All other inhibitors were purchased from Biomol (Plymouth Meeting, PA, USA). The inhibitors were dissolved in dimethylsulfoxide (DMSO) and were added to the cultures from a 1000-fold concentrated stock. Control cultures received similar amounts of DMSO only. Final DMSO concentrations did not exceed 0.1%. R1881 methyltrienolone, New England Nuclear) and Casodex (bicalutamide, Zeneca) were dissolved in ethanol. Control cultures were treated with ethanol only. The ®nal ethanol concentration did not exceed 0.1%.
Promoter-reporter studies
The 178 bp FAS promoter-reporter constructs pFASwt-luc and pFASdelSRE-luc, in which the complex SREBP-binding site was deleted, were described before (Swinnen et al., 1997b) . pSYNwt-luc was generated by insertion of a PCR fragment (from base 7468 to base 799 of the published human HMG-CoA synthase promoter (Inoue et al., 1998) ) into pGL3 (Promega). The constructs pSYNmutSRE1 and pSYNmutSRE2, were made by site directed mutagenesis of the parent plasmid pSYNwt-luc as described (Inoue et al., 1998) , using a QuikChange site-directed mutagenesis kit (Stratagene). LNCaP cells were plated on day 0 in 60 mm dishes in RPMI containing 10% FCS at a density of 1610 6 cells/dish. The next day transfection mixtures were prepared. For each plate, 2 ml of serum-free DMEM medium (Life Technologies) was supplemented with 5 mg of promoterreporter construct. Where indicated 200 ng of an expression vector encoding dominant negative MEK (MEK2a-EE-CMV(S218A, S222A), kindly provided by Dr D Templeton, Case Western Reserve University, Cleveland, Ohio) or a matching empty expression vector (EE-CMV) was added. After addition of 15 ml Transfast (Promega) the transfection mixture was incubated for 15 min at room temperature. Cells were washed with serum-free medium, the transfection mixture was added and cultures were incubated for 30 min in the CO 2 incubator. Three ml RPMI with 5% FCS was added. On day 2, cultures were serum-starved for 4 h and treated as indicated in the legends to the ®gures. To assess the impact of cholesterol depletion, cells were incubated in medium supplemented with 5% lipoprotein de®cient serum (Perimmune, Rockville, MD, USA) in the presence of either mevastatin (10 mM) or 25-hydroxycholesterol (1 mg/ml). On day 3 the cells were washed with PBS and lysed in 500 ml passive lysis buer (Promega). Aliquots of 10 ml of cleared lysate were assayed for luciferase activity by using a luciferase reporter assay kit from Promega and a Berthold Microlumant LB 96P luminometer.
RNA preparation and analysis
LNCaP cells were plated in 150 mm dishes at a density of 3610 6 cells/dish in RPMI 1640 medium containing 10% FCS. The next day cells were washed with serum-free medium and serum-starved for 2 days. The medium was replaced and cells were treated as described in the legends to the ®gures. After 24 h of incubation, plates were washed with PBS, snap-frozen in liquid nitrogen and stored at 7808C. Total RNA was prepared and analysed for FAS expression as described before (Swinnen et al., 1997a) . A SREBP-1 probe was prepared by random prime labeling of a 4.2 kb BamHI/SalI insert of plasmid pSREBP-1a obtained from ATCC (ATCC number 79810) (Yokoyama et al., 1993) Speci®c SREBP-1a and SREBP-1c probes were prepared by PCR using the primers described by Shimomura et al. (1997) . Equal loading of RNA was veri®ed by hybridization with a probe for 18S ribosomal RNA (Verhoeven et al., 1995) .
Immunodetection of FAS
LNCaP cells were plated in 60 mm dishes at a density of 1.5610 6 cells/dish in RPMI 1640 medium containing 10% FCS. The next day cells were washed with serum-free medium and serum-starved for 1 day. The medium was replaced and cells were treated as described in the legends to the ®gures. After 40 h of incubation, plates were washed with PBS and cells were collected in 16SDS-sample buer. Protein concentrations were determined on diluted samples using a BCA procedure (Pierce). Equal amounts of protein were separated on a 5% SDS-polyacrylamide gel and blotted onto PVDF membranes (Roche). Membranes were blocked in TBS with 5% non-fat dry milk and incubated with a monoclonal anti-Fas antiserum according to the manufacturer's instructions (Transduction Laboratories, Lexington, KY, USA). Immuno-reactive signals were detected by incubation with an HRP-conjugated rabbit anti-mouse secondary antibody (Dako) followed by chemiluminescent detection of immunoreactive proteins (Renaissance, New England Nuclear, Dreiech, Germany). Experiments were performed twice under similar conditions.
Assay of FAS activity
LNCaP cells were plated and treated as described above (Immunodetection of FAS). After 40 h of incubation, plates were washed with PBS, cells were collected by scraping and centrifugation and frozen at 7808C. FAS activity was determined and expressed per mg cellular DNA as described before (Swinnen et al., 1997a) .
Oil red O staining
Cells were plated in 60 mm dishes in RPMI 1640 medium containing 10% FCS at a density of 1.5610 6 cells/dish. The next day cells were washed with serum-free medium and serum-starved for 1 day. The medium was replaced and cells were incubated in the absence or presence of 10 ng/ml EGF for 4 days. After ®xation in 4% formaldehyde in PBS, cultures were stained with Oil red O and counterstained with methylgreen as described before (Swinnen et al., 1996) .
Immunodetection of SREBP-1
LNCaP cells were seeded in 15 cm dishes at a density of 3610 6 cells in RPMI medium supplemented with 5% CT-FCS. Two or three days later, the medium was replaced and cultures were treated with EGF. At the indicated times after treatment cells were harvested, nuclear fractions were prepared and presence of SREBP-1 was assessed by Western blot analysis as described before (Swinnen et al., 1997b) .
Treatment with recombinant adenovirus
The construction and propagation of recombinant adenoviruses expressing a dominant-negative form of SREBP-1 (Ad-DN) and of adenoviruses without insert (Ad-Null) were described before (Foretz et al., 199a, b) . On day 0, cells were seeded in 10 cm dishes at a density of 2610 6 cells in RPMI medium supplemented with 5% CT-FCS. The next day, medium was removed and 5 ml fresh medium was added. Virus was added as indicated. Cultures were incubated for 4 h with frequent agitation. Fresh medium was added to a ®nal volume of 10 ml. On day 2, cultures were treated with EGF (10 ng/ml) as indicated. On day 3, cells were washed and quick-frozen for RNA preparation as described before (Swinnen et al., 1997a) .
